This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The fall program of the American Neurotology Society was held in Minneapolis, Minn, on October 1, 1993.
The number of clinical applications for otoacoustic emissions testing has grown exponentially since Kemp's 1978 report, according to neurophysiologist Brenda Lonsbury-Martin, PhD. The emissions are sounds generated by the cochlea and are classified as spontaneous or evoked, the latter in response to a test stimulus such as a click or a tone. Advantages include the brevity, objectivity, and reliability of this simple, noninvasive test. Current areas of use of otoacoustic emissions testing include neonatal screening, serial testing in Meniere's disease, and assessment of hearing loss in the range of 2000 to 4000 Hz, which may present a problem for auditory brain-stem–evoked responses. Possible use in combination with other auditory test batteries, including electrocochleography and intraoperative monitoring, offer exciting prospects for otoacoustic emissions testing in the near future.
An investment of research energy
O'Leary M. Fall Program of the American Neurotology Society. Arch Otolaryngol Head Neck Surg. 1994;120(2):240. doi:10.1001/archotol.1994.01880260106024
Otolaryngology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.